The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRMD | +10.69% | +120.4% | +17.1% | -26% |
| S&P | +19.89% | +109.18% | +15.89% | +491% |
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
The company announced a stock sale and the sale of prefunded warrants.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $39.74M | 4829.4% |
| Gross Profit | $37.87M | 12683.3% |
| Gross Margin | 95.31% | 58.6% |
| Market Cap | $835.60M | 251.1% |
| Market Cap / Employee | $12.86M | 0.0% |
| Employees | 65 | -20.7% |
| Net Income | $19.83M | 240.1% |
| EBITDA | $19.71M | 229.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $159.31M | 458.2% |
| Accounts Receivable | $42.91M | 20696.9% |
| Inventory | 9.6 | 140.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.26M | -40.7% |
| Short Term Debt | $0.18M | 11.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 32.97% | 125.5% |
| Return On Invested Capital | -46.62% | 9.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $29.97M | 312.9% |
| Operating Free Cash Flow | $29.99M | 313.6% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 27.33 | 16.50 | - | ||
| Price to Book | 9.67 | 7.99 | 4.69 | 7.26 | 77.01% |
| Price to Sales | 38.76 | 11.46 | 5.15 | 7.29 | -97.64% |
| Price to Tangible Book Value | 10.10 | 8.25 | 4.79 | 7.38 | 73.61% |
| Price to Free Cash Flow TTM | 29.14 | - | |||
| Enterprise Value to EBITDA | -135.48 | 34.11 | 17.15 | 35.31 | -362.23% |
| Free Cash Flow Yield | 3.4% | - | |||
| Return on Equity | -65.0% | -23.2% | 19.9% | 38.3% | -134.38% |
| Total Debt | $0.56M | $0.52M | $0.48M | $0.44M | -26.77% |
CRMD earnings call for the period ending December 31, 2024.
CRMD earnings call for the period ending September 30, 2024.
CRMD earnings call for the period ending June 30, 2024.
CRMD earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
